BioSpace News Archive

The investigational drug directs a patient’s own IL-2 toward immune activation while simultaneously preventing IL-2’s immune suppression activities.

If bentracimab continues to yield the desired results through the rest of the Phase III study, PhaseBio will be on track to file a Biologics License Application in mid-2022.

Lexicon Pharmaceuticals, Inc., announced that a new analysis evaluating the clinical benefit of Lexicon’s investigational drug, sotagliflozin, in heart failure and blood glucose control across the full range of kidney function was presented at the virtual American Heart Association Scientific Sessions 2021.

Innovent Biologics, Inc. announces that the results of the Phase Ib clinical trial of IBI302, a first-in-class ophthalmic recombinant human anti-VEGF and anti-complement bi-specific fusion protein for neovascular age-related macular degeneration is released in e-poster at 2021 American Academy of Ophthalmology.

BeiGene and NewBridge Pharmaceuticals announced that BRUKINSA® has received approval from the Saudi Food and Drug Authority for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.

InnoCare Pharma, a commercial-stage biotech company, announced the Investigational New Drug clearance of its SHP2 allosteric inhibitor ICP-189 by the US Food and Drug Administration for starting clinical trial in the United States.

89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, announced the presentation of new data from a post-hoc analysis of the Phase 1b/2a proof-of-concept study evaluating BIO89-100 in patients with nonalcoholic steatohepatitis at The Liver Meeting® 2021 of the American Association for the Study of Liver Diseases.

Mesoblast Limited announced that results from the randomized, controlled Phase 3 trial of rexlemestrocel-L in 565 patients with New York Heart Association class II and class III chronic heart failure with reduced ejection fraction were presented as a late breaking presentation at the American Heart Association annual Scientific Sessions during a featured program titled ‘Building on the Foundations of Treatment: Advances in Heart Failure Therapy’.

Antengene Corporation Limited, a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, announced the presentation of three posters at the Society for Immunotherapy of Cancer Annual Meeting in Washington D.C..

Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. announces that the protocols of Phase II and III clinical trials of ASC42 to treat patients with primary biliary cholangitis has been approved by China National Medical Products Administration.